PriceTargets.com logo

NASDAQ:BCAB - BioAtla Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $48.00
  • Forecasted Upside: 3.56 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$46.35 As of 01/26/2021 01:00 AM ET
▼ -0.83 (-1.76%)
1 month | 3 months | 12 months
Get New BioAtla Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCAB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$48.00
▲ +3.56% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for BioAtla in the last 3 months. The average price target is $48.00, with a high forecast of $51.00 and a low forecast of $45.00. The average price target represents a 3.56% upside from the last price of $46.35.
Buy
The current consensus among 4 investment analysts is to buy stock in BioAtla.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/11/2021Credit Suisse GroupInitiated CoverageOutperform$49.00High
i
1/11/2021Jefferies Financial GroupInitiated CoverageBuy$51.00High
i
1/11/2021JPMorgan Chase & Co.Initiated CoverageOverweight$45.00High
i
1/11/2021BTIG ResearchInitiated CoverageBuy$47.00High
i
(Data available from 1/27/2016 forward)
BioAtla logo
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.
Read More

Today's Range

Now: $46.35
$45.72
$47.84

50 Day Range

MA: N/A

52 Week Range

Now: $46.35
$27.15
$49.49

Volume

129,338 shs

Average Volume

237,709 shs

Market Capitalization

$1.49 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of BioAtla?

The following equities research analysts have issued stock ratings on BioAtla in the last twelve months: BTIG Research, Credit Suisse Group AG, Jefferies Financial Group Inc., and JPMorgan Chase & Co..

What is the current price target for BioAtla?

4 Wall Street analysts have set twelve-month price targets for BioAtla in the last year. Their average twelve-month price target is $48.00, suggesting a possible upside of 3.6%. Jefferies Financial Group Inc. has the highest price target set, predicting BCAB will reach $51.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $45.00 for BioAtla in the next year.

What is the current consensus analyst rating for BioAtla?

BioAtla currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BCAB will outperform the market and that investors should add to their positions of BioAtla.

What other companies compete with BioAtla?

Other companies that are similar to BioAtla include Pacific Biosciences of California, Integra LifeSciences, Envista, Swedish Orphan Biovitrum AB (publ), Emergent BioSolutions, Hikma Pharmaceuticals PLC (HIK.L), SmileDirectClub, Certara, Inspire Medical Systems, Elekta AB (publ), Blueprint Medicines, Evotec SE (EVT.F), Maravai LifeSciences, Omnicell and Biohaven Pharmaceutical.

How do I contact BioAtla's investor relations team?

The company's listed phone number is 858 558 0708. The official website for BioAtla is www.bioatla.com.